WO2007123818A3 - Organic nitric oxide enhancing salts of prostaglandins, compositions and methods of use - Google Patents

Organic nitric oxide enhancing salts of prostaglandins, compositions and methods of use Download PDF

Info

Publication number
WO2007123818A3
WO2007123818A3 PCT/US2007/008427 US2007008427W WO2007123818A3 WO 2007123818 A3 WO2007123818 A3 WO 2007123818A3 US 2007008427 W US2007008427 W US 2007008427W WO 2007123818 A3 WO2007123818 A3 WO 2007123818A3
Authority
WO
WIPO (PCT)
Prior art keywords
nitric oxide
treating
organic
oxide enhancing
prostaglandins
Prior art date
Application number
PCT/US2007/008427
Other languages
French (fr)
Other versions
WO2007123818A2 (en
Inventor
David S Garvey
Original Assignee
Nitromed Inc
David S Garvey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitromed Inc, David S Garvey filed Critical Nitromed Inc
Publication of WO2007123818A2 publication Critical patent/WO2007123818A2/en
Publication of WO2007123818A3 publication Critical patent/WO2007123818A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides compositions and kits comprising at least one organic nitric oxide enhancing salt of a prostaglandin, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods, for'(a) treating ophthalmic disorders; (b) treating cerebrovascular disorders; (c) treating cardiovascular disorders; (d) treating benign prostatic hyperplasia (BPH); (e) treating peptic ulcers; (e) treating sexual dysfunctions and (f) inducing abortions. The organic nitric oxide enhancing compounds that form salts with the prostaglandins are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and/or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.
PCT/US2007/008427 2006-04-18 2007-04-04 Organic nitric oxide enhancing salts of prostaglandins, compositions and methods of use WO2007123818A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79264406P 2006-04-18 2006-04-18
US60/792,644 2006-04-18

Publications (2)

Publication Number Publication Date
WO2007123818A2 WO2007123818A2 (en) 2007-11-01
WO2007123818A3 true WO2007123818A3 (en) 2008-12-11

Family

ID=38625512

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/008427 WO2007123818A2 (en) 2006-04-18 2007-04-04 Organic nitric oxide enhancing salts of prostaglandins, compositions and methods of use

Country Status (1)

Country Link
WO (1) WO2007123818A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9579270B2 (en) 2000-03-31 2017-02-28 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
CA2647859C (en) 2006-03-29 2016-01-05 Nitromed, Inc. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US9045505B2 (en) 2006-09-28 2015-06-02 University Of Otago Nitric oxide donors
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
WO2010110684A1 (en) * 2009-03-27 2010-09-30 Robin Andrew James Smith Nitric oxide donors
ES2687494T3 (en) * 2011-01-19 2018-10-25 Topokine Therapeutics, Inc. Methods and compositions to reduce body fat
US20150011755A1 (en) * 2012-02-07 2015-01-08 Dr. Reddys Laboratories Limited Amine salts of prostaglandin analogs
CN108753898A (en) * 2018-04-09 2018-11-06 深圳市祥根生物科技有限公司 A kind of preparation method and its usage of Misoprostol acid
CN113943266A (en) * 2021-11-18 2022-01-18 广州楷石医药有限公司 Nitric oxide donor type beraprost derivative and pharmaceutical composition and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176238B1 (en) * 1999-03-01 2007-02-13 Nitromed Inc. Nitrostated and nitrosylated prostaglandins, compositions and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176238B1 (en) * 1999-03-01 2007-02-13 Nitromed Inc. Nitrostated and nitrosylated prostaglandins, compositions and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9579270B2 (en) 2000-03-31 2017-02-28 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins

Also Published As

Publication number Publication date
WO2007123818A2 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
WO2007123818A3 (en) Organic nitric oxide enhancing salts of prostaglandins, compositions and methods of use
WO2006099058A3 (en) Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
WO2006127591A3 (en) Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
ATE512954T1 (en) N-PHENYLDIOXOHYDROPYRIMIDINES SUITABLE AS INHIBITORS OF HEPATITIS C VIRUS (HCV).
NO20064894L (en) Beta-carbolines useful for the treatment of inflammatory diseases
NO20072665L (en) Rapamycin derivatives and their use in the treatment of neurological disorders
BRPI0506736A (en) stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
WO2007113830A3 (en) Kit for treating skin infection
ATE483778T1 (en) COOLANT COMPOSITION
WO2006071609A3 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2006137009A3 (en) Fluorescent sulfonamide derivatives having carbonic anhydrase inhibiting activity and their use as therapeutic and diagnostic agents
WO2006041855A3 (en) Compositions and methods using apocynin compounds and nitric oxide donors
WO2007097981A3 (en) Alpha carbolines and uses thereof
AR046943A1 (en) DERIVATIVES OF 2-PIRIDINILETILBENZAMIDA, A PROCEDURE FOR THEIR PREPARATION, FUNGICIDE COMPOSITIONS THAT CONTAIN IT AND ITS USE IN THE CONTROL OF PHYTO-PATHOGEN FUNGI
WO2006055542A3 (en) Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use
WO2006042103A3 (en) Reversible inhibitors of cathepsin b
WO2010021934A3 (en) Azaindole inhibitors of iap
WO2007016136A3 (en) Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
WO2007086884A3 (en) Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
WO2008021194A3 (en) Adsorbent composition for desulfuring a fluid, method and apparatus for its use
WO2007075541A3 (en) Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
DE602006020585D1 (en) NEW CYSTONE PROTEASE INHIBITORS AND ITS THERAPEUTIC APPLICATION
WO2007126609A8 (en) Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
AR064564A1 (en) DERIVATIVES OF N-ALQUINYL CARBOXAMIDE, A PROCEDURE FOR THEIR PREPARATION, A FUNGITIVE COMPOSITION THAT UNDERSTANDS THEM AND A METHOD TO COMBAT PHYTO-PATHOGEN FUNGI THAT USES THEM.
SE0701694L (en) New bronchodilating a, b unsaturated amides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07754873

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07754873

Country of ref document: EP

Kind code of ref document: A2